missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Natalizumab Chimeric Recombinant Rabbit Monoclonal Antibody (Natalizumab)

Description
Specificity: This antibody binds to the alpha 4 binds subunit of alpha-4Beta1 (also known as very late antigen 4 [VLA-4] or CD49d-CD29) and alpha-4Beta7 integrin.
Natalizumab is a recombinant, humanized monoclonal antibody, binds to alpha4beta1-integrinand blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.
Specifications
Specifications
| Antigen | Natalizumab Chimeric |
| Applications | Flow Cytometry, Inhibition Assays |
| Classification | Recombinant Monoclonal |
| Clone | Natalizumab |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% ProClin 300 |
| Gene Alias | AN 100226; BG00002 |
| Host Species | Rabbit |
| Immunogen | The RAMOS cell line, a non-EBV releasing cell line, injected into mice. |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?